Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 19/20 | 0.49 |
| ▸ | RXRB | P28702 | 3/20 | 0.46 |
| ▸ | RXRG | P48443 | 3/20 | 0.46 |
| ▸ | RARA | P10276 | 2/20 | 0.46 |
| ▸ | RARB | P10826 | 2/20 | 0.46 |
| ▸ | RARG | P13631 | 2/20 | 0.46 |
| ▸ | HNF4A | P41235 | 5/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6472792 | 0.91 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL4859743 | 0.87 | RXRA (0.51) | RXRARXRBRXRGRARARARB | |
| SCHEMBL5846427 | 0.81 | RXRA (0.37) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6473706 | 0.78 | LIPE (0.56) | RXRAHNF4A | |
| SCHEMBL5364822 | 0.78 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL7213482 | 0.77 | RXRA (0.48) | RXRARXRBRXRGRARARARB | |
| SCHEMBL727284 | 0.77 | RXRA (0.60) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6914132 | 0.77 | RXRA (0.54) | RXRARXRBRXRGRARARARB | |
| SCHEMBL16316083 | 0.77 | RXRA (0.47) | RXRARXRBRXRGRARARARB | |
| SCHEMBL6472243 | 0.77 | RXRA (0.40) | RXRARXRBRXRGRARARARB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6924388-B2 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-02 | — | — | US | disclosed |
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2004-05-13 | — | — | US | disclosed |
| US-6632963-B1 | Are useful for the treatment of a wide variety of disease states, whether human or veterinary, for example dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, as well as for the treatment of | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2003-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092594-A1 | Bicyclic aromatic compounds and pharmaceutical/cosmetic compositions comprised thereof | AHR, TYR, MC1R | RXRA 174/4885RXRB 259/4885RXRG 209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.